Obstructive sleep apnea (OSA) is a sleep disorder commonly secondary to obesity that has detrimental effects on health and quality of life. Thus, weight loss is one of the mainstays of OSA treatment. Tirzepatide, a novel glucagon-like peptide-1 (GLP-1) and glucagon-dependent insulinotropic polypeptide (GIP) dual agonist, demonstrated significant glycemic control and weight loss. This literature review analyzes the current literature on tirzepatide's effects on OSA, mechanism of action, complications, and off-label uses/indications. Also, this review offers potential insights into how tirzepatide and other GLP-1 medications can be repurposed for other metabolic conditions and their associated sequelae.
Authors
Wen, Jimmy; Nadora, Denise; Truong, Alina; Bernstein, Ethan; How-Volkman, Christiane; Razick, Daniel I; Akhtar, Muzammil; Razick, Adam A; Frezza, Eldo
Keywords
glp-1 agonistobstructive sleep apneaosatirzepatideweight loss